Recurrent Breast Cancer Completed Phase 2 Trials for Saracatinib (DB11805)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00559507Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By SurgeryTreatment